Scorching COVID-19 Era Returns From India Biotech, Healthcare Funds Outpace The Globe
Indian E-pharmacies, Online Consulting Firms Raise Over $740m
Early COVID-19 therapies including Gilead’s remdesivir, China-plus procurement policies, vaccine partnerships and a dovish stance by the central bank led to returns on India biotech and healthcare funds outperforming global returns. Meanwhile, funding for e-pharmacies and online consulting firms gathered pace.
